The primary objective of this study is: to evaluate whether GS-6624 is effective at preventing the progression of liver fibrosis in subjects with NASH.
Males and females 18 - 65 years of age with NASH, are willing to have a liver biopsy and meeting all of the study’s entry criteria will be randomly assigned in a 1:1:1 ratio to treatment with weekly subcutaneous injections in 1 of 3 different treatment arms:
* Treatment Arm A: 75 mg of GS-6624
* Treatment Arm B: 125 mg of GS-6624
* Treatment Arm C: Placebo
The treatment phase of the study will last 96 weeks.
Subjects will be reimbursed $50 and a parking pass at each scheduled visit.
For more information, contact Melissa Wagner at 919-684-4798.